Results 91 to 100 of about 8,656 (193)

Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins

, 2011
Cardiovascular disease (CVD) risk in type 2 diabetes (T2DM) is only partially reduced by intensive glycemic control. Diabetic dyslipidemia is suggested to be an additional important contributor to CVD risk in T2DM.
Koska Juraj, Ansar Sameer, Juraj Koska, Reaven Peter D, Sameer Ansar, Peter D Reaven   +5 more
core   +1 more source

Obituary for Prof. Dr. med. Dr. h. c. Werner Creutzfeldt, FRCP [PDF]

, 2006
Burkhard Göke, Göke, Burkhard
core   +1 more source

The Role and Mechanism of Incretins in Gynaecologic Diseases. [PDF]

Endocrinol Diabetes Metab
Yan J, Cao M, Ding Y, Zhang Y, Sun Y, Jiang G, Zhang Y, Kang L, Zhou X, Luo J, Li B.   +10 more
europepmc   +1 more source

The Framework of Precision Pharmacotherapy in Metabolic Dysfunction-Associated Steatohepatitis: A Network Meta-Analysis. [PDF]

Clin Pharmacol Ther
Chen Y, Yang X, Shen W, Zhang P, Yang X, Xu X, Lu D.   +6 more
europepmc   +1 more source

Changes in GLP-1 and GIP During Endurance Training in Competitive Triathletes: A Pilot Observational Study. [PDF]

J Clin Med
Wiciński M, Kuźmiński O, Konopacka K, Kowalka W, Słomko W, Gierach M.   +5 more
europepmc   +1 more source

Rise or fall? Reconciling contested directions in human gut hormone aging. [PDF]

Front Endocrinol (Lausanne)
Mavrych V, Shypilova I, Bolgova O.
europepmc   +1 more source

Weight management in cardiology practice: challenges and opportunities. [PDF]

Neth Heart J
Leening MJG, Martens FMAC, Hemels MEW.
europepmc   +1 more source

The molecular mechanisms of incretin resistance in Type 2 Diabetes Mellitus (T2DM). [PDF]

Nutr Diabetes
Albaghlany RM, Mansour AA.
europepmc   +1 more source

Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia. [PDF]

MedComm (2020)
Musso G, Pinach S, Mella A, De Michieli F, Calabrese A, Trifiro D, Petrangolini G, Cassader M, Mariano F, Gambino R.   +9 more
europepmc   +1 more source

The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia? [PDF]

Med Sci (Basel)
Mizdrak M, Batistić D, Mizdrak I.
europepmc   +1 more source